US 12,447,169 B2
Maribavir isomers, compositions, methods of making and methods of using
John D. Peabody, III, West Chester, PA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Sep. 9, 2024, as Appl. No. 18/828,652.
Application 18/200,636 is a division of application No. 16/983,310, filed on Aug. 3, 2020, granted, now 11,684,632, issued on Jun. 27, 2023.
Application 16/983,310 is a division of application No. 16/663,743, filed on Oct. 25, 2019, granted, now 10,765,692, issued on Sep. 8, 2020.
Application 16/663,743 is a division of application No. 15/291,639, filed on Oct. 12, 2016, granted, now 10,485,813, issued on Nov. 26, 2019.
Application 15/291,639 is a division of application No. 15/055,043, filed on Feb. 26, 2016, abandoned.
Application 18/828,652 is a continuation of application No. 18/597,197, filed on Mar. 6, 2024, abandoned.
Application 18/597,197 is a continuation of application No. 18/200,636, filed on May 23, 2023, abandoned.
Application 15/055,043 is a continuation of application No. 14/595,548, filed on Jan. 13, 2015, abandoned.
Application 14/595,548 is a continuation of application No. 13/282,501, filed on Oct. 27, 2011, granted, now 8,940,707, issued on Jan. 27, 2015.
Claims priority of provisional application 61/407,637, filed on Oct. 28, 2010.
Prior Publication US 2024/0424009 A1, Dec. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7056 (2006.01); A61K 45/06 (2006.01); G01N 33/94 (2006.01); G09B 19/00 (2006.01)
CPC A61K 31/7056 (2013.01) [A61K 45/06 (2013.01); G01N 33/94 (2013.01); G09B 19/00 (2013.01); G01N 2430/00 (2013.01); G01N 2800/52 (2013.01)] 8 Claims
 
1. A method of treating a cytomegalovirus (CMV) infection in a patient having a CMV infection, the method comprising orally administering to the patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole in an amount of 400 mg twice a day.